Thomas J. Schall

CIK: 0001423084

Transaction Breakdown

Open Market Buys (P)3 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IMRX

Immuneering Corp

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

IMRX
Immuneering Corp
Jun 11, 2026
Award(A)
Stock Option
Direct
33.4K shares-
IMRX
Immuneering Corp
Jan 15, 2026
Purchase(P)
Direct
21.6K shares at avg. $4.67$101K
IMRX
Immuneering Corp
Jun 27, 2025
Purchase(P)
Direct
9.5K shares at avg. $3.66$35K
IMRX
Immuneering Corp
Jun 17, 2025
Purchase(P)
Direct
40.5K shares at avg. $2.21$89K
IMRX
Immuneering Corp
Jun 13, 2025
Award(A)
Stock Option
Direct
33.4K shares-

		Type	Shares	Price		Ownership
Jun 11, 2026	IMRX Immuneering Corp	Award(A) Stock Option	33,350	-	-	Direct
Jan 15, 2026	IMRX Immuneering Corp	Purchase(P)	21,645	$4.67	$101,041	Direct
Jun 27, 2025	IMRX Immuneering Corp	Purchase(P)	9,500	$3.66	$34,788	Direct
Jun 17, 2025	IMRX Immuneering Corp	Purchase(P)	40,485	$2.21	$89,278	Direct
Jun 13, 2025	IMRX Immuneering Corp	Award(A) Stock Option	33,350	-	-	Direct

1-5 of 5 transactions

About Schall Thomas J.

Schall Thomas J. (SEC CIK 0001423084) files insider reports with the SEC as Director of Immuneering Corp (IMRX).

Signal8 holds 5 ownership filings by Schall Thomas J., all Form 4s, filed between Jun 16, 2025 and Jun 11, 2026. Those filings report 5 transactions, from Jun 13, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Schall Thomas J.'s filings is in CAMBRIDGE, MA.

Recent filings by Schall Thomas J.

Jun 11, 2026: Grant or award of IMRX derivative securities (Form 4, code A).
Jan 15, 2026: Open-market purchase of IMRX shares (Form 4, code P).
Jun 27, 2025: Open-market purchase of IMRX shares (Form 4, code P).
Jun 17, 2025: Open-market purchase of IMRX shares (Form 4, code P).
Jun 13, 2025: Grant or award of IMRX derivative securities (Form 4, code A).

Other insiders filing for Immuneering Corp (IMRX)

Gengos Andrew, Chief Financial Officer
Zeskind Benjamin J., PRESIDENT AND CEO
Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER
HAUSMAN DIANA, Director
CARPENTER ROBERT J, Director
KEATING LAURIE, Director

How to read Form 4 transaction codes